Beam Therapeutics
BEAM
Market cap $1.92B

19.13 USD

+0.89

4.88%

At close Apr 22, 4:00 PM EDT

Pre-market

19.08

-0.05

0.26%

1 day

4.88%

5 days

13.94%

1 month

-20.32%

3 months

-27.51%

6 months

-15.88%

Year to date

-22.55%

1 year

-20.62%

5 years

14.83%

10 years

2.03%

About: Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Employees: 483

Healthcare Biotechnology

0

Funds holding %

of 7,419 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

81% more call options, than puts

Call options by funds: $6.97M | Put options by funds: $3.86M

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

28% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 64

5% more funds holding

Funds holding: 220 [Q3] → 231 (+11) [Q4]

2.48% more ownership

Funds ownership: 95.88% [Q3] → 98.36% (+2.48%) [Q4]

4% more capital invested

Capital invested by funds: $1.94B [Q3] → $2.02B (+$85.8M) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$26

36%

upside

Avg. target

$50

161%

upside

High target

$80

318%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio 14% 1-year accuracy 26 / 187 met price target	318%upside $80	Buy Reiterated	7 Apr 2025
B of A Securities Alec Stranahan 0% 1-year accuracy 0 / 8 met price target	120%upside $42	Buy Upgraded	28 Mar 2025
Scotiabank Greg Harrison 24% 1-year accuracy 10 / 41 met price target	109%upside $40	Sector Outperform Upgraded	10 Mar 2025
Jones Trading Soumit Roy 15% 1-year accuracy 2 / 13 met price target	78%upside $34	Buy Upgraded	10 Mar 2025
Guggenheim Debjit Chattopadhyay 17% 1-year accuracy 4 / 23 met price target	308%upside $78	Buy Reiterated	27 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about BEAM published over the past 30 days

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3)

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Schaeffers Research

Power Ranking Our Top Stock Picks of 2025

Subscribers to Chart of the Week received this commentary on Sunday, March 30.

Power Ranking Our Top Stock Picks of 2025

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

Zacks Investment Research

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S.

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Recently, BEAM reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. Unfortunately, they concurrently announced a $500 million equity offering, which may have caused concerns about near-term dilution. Still, BEAM-302 has innovative in vivo base editing technology that could potentially offer a one-time curative therapy for patients suffering from AATD.

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Schaeffers Research

3 Gene Therapy Stocks to Watch Amid Industry Turmoil

Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06.

3 Gene Therapy Stocks to Watch Amid Industry Turmoil

Zacks Investment Research

BEAM Down Despite Positive Initial Data From Genetic Disorder Study

Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.

BEAM Down Despite Positive Initial Data From Genetic Disorder Study

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

On Monday, Beam Therapeutics Inc. BEAM announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing.

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Beam Therapeutics Announces Pricing of Underwritten Offering

CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of an underwritten offering of 16,151,686 shares of its common stock at an offering price of $28.48 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant, before deducting underwriter discounts and commissions and estimated offering expenses. Each pre-funded warrant will have an exercise price of $0.01 per share, will be exercisable immediately and will be exercisable until exercised in full. Gross proceeds from the offering are expected to be approximately $500.0 million. All of the securities in the offering are to be sold by Beam Therapeutics. The offering is expected to close on or about March 11, 2025, subject to customary closing conditions.

Beam Therapeutics Announces Pricing of Underwritten Offering

See News Rankings

Charts implemented using Lightweight Charts™